Compare Amgen, Inc. (AMGN) vs Illinois Tool Works Inc. (ITW) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs Illinois Tool Works Inc. — how do they compare? Amgen, Inc. trades at $363.66 (market cap $196.12B), while Illinois Tool Works Inc. trades at $269.23 (market cap $77.34B). The key difference: Amgen, Inc. is far larger — about 2.5× Illinois Tool Works Inc.'s market cap, and Amgen, Inc. pays the higher dividend (2.77%). Which is the better fit depends on your goals.
| AMGN | ITW | |
|---|---|---|
Market Cap | $196.12B | $77.34B |
Sector | Health | Industrials |
52-Week High | $388.16 | $299.60 |
52-Week Low | $271.18 | $241.07 |
Enterprise Value | $241.41B | $85.66B |
Dividend Yield | 2.77% | 2.4% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
ITW trades at $268.81, up 1.25% with a bullish technical signal and strong profitability metrics including 19.32% net margin and 96.88% ROE. Recent earnings beats and a $1.61 dividend payment reflect operational strength, though cash flow trends show slight volatility. The stock is near resistance at $268 with analyst consensus target of $284.50.
Outlook remains positive with consistent earnings outperformance and margin expansion from enterprise initiatives. Risks include construction sector weakness and currency exposure. Wall Street shows mixed sentiment with 21% buy ratings, suggesting cautious optimism amid near-term headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Illinois Tool Works Inc.
Illinois Tool Works is a diversified global manufacturer that produces specialized industrial equipment, consumables, and related services. The firm operates 87 global divisions through seven distinct operating segments: automotive OEM, construction products, food equipment, specialty products, test/measurement and electronics, polymers and fluids, and welding. About half of its revenue comes from its operations in North America, with the remainder originating from international markets. ITW takes a bottom-up and decentralized approach to portfolio management, with the exception that each segment must apply its 80/20 operating process modeled on the Pareto principle.
Read more on ITW →
